- Visibility 108 Views
- Downloads 26 Downloads
- Permissions
- DOI 10.18231/j.ijpca.2021.024
-
CrossMark
Simultaneous analysis of eprosartan and hydrochlorothiazide in tablet formulation by High- Performance thin layer chromatography with ultraviolet absorption densitometry
Abstract
A new, simple, accurate, and precise high-performance thin-layer chromatographic method has been established for simultaneous analysis of Eprosartan and Hydrochlorothiazide from a tablet formulation. Standard and sample solutions of Eprosartan and Hydrochlorothiazide were applied to precoated 250 μm layer of silica gel G 60 F254 and the plates were developed with Chloroform: Acetonitrile: Glacial Acetic Acid (7:3:1,v/v/v) as mobile phase. Detection and evaluation of densitograms was performed densitometrically at 254 nm. The linear range was 200-700 ng/band with the retention factors of Eprosartan and Hydrochlorothiazide were 0.26± 0.02 and 0.44±0.02, respectively. The method was validated and successfully used for analysis of the drugs in tablets.
Introduction
Eprosartan (EPS), (E)-3-[2-butyl-1-[(4 carboxyphenyl)methyl]-1H-imidazol-5-yl]-2-[(2 thienyl)methyl]propenoic acid ([Figure 1])A, is a highly selective, non-peptide angiotensin-II antagonist. It has been shown to inhibit angiotensin-II induced vasoconstriction and to reduce systolic and diastolic blood pressure.[1] Hydrochlorothiazide (HYT), 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide-1,1-dioxide ([Figure 1])B is a diuretic drug.[2] The rationale behind use of this drug combination is that in treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. Oral administration of EPS with HYT has been found to be more effective than use of either drug alone.[3]
Other work dealing with analysis of EPS and other drugs in pharmaceuticals and biological samples includes use of LC–MS–MS,[4] capillary zone electrophoresis,[5] and micellar electrokinetic capillary chromatography.[6] Analysis of EPS in biological samples by HPLC–UV[7] and a chemometric method for optimization of solid-phase extraction HPLC–UV[8] of EPS in plasma have also been reported. There are several reports of the analysis of HYT individually or in combination with other drugs, including use of HPLC, HPTLC, spectrophotometry, and non-aqueous potentiometric titration.[9], [10], [11], [12] As far as we are aware, no validated HPTLC method for analysis of EPS and HYT in bulk and in tablets has been reported in the literature. The purpose of this research was to establish such a method and, after validation in accordance with International Conference on Harmonization (ICH) guidelines and the directives for good laboratory practice,[13], [14], [15], [16], [17] to use the method for analysis of the drug content of tablets.
Materials and Methods
Materials
EPS and HYT were received as a gift sample from Abbott Laboratories. Methanol (HPLC grade) was purchased from MERCK Specialities Private Limited. AR grade Ethyl acetate, Ammonia solution, Chloroform, Acetonitrile and Glacial Acetic Acid were purchased from ANALAB fine chemicals, Mumbai. The tablet formulation containing 600 mg of EPS and 25 mg of HYT (Teveten HCT) was purchased from local market.
Instrumentation and chromatographic condition
Chromatography was performed on 20 cm × 10 cm aluminum-backed TLC plates, coated with 250 μm layer of silica gel G 60 F254 ( E. Merck, Darmstadt, Germany supplied by Anchrom Technologists, Mumbai). The solubility of EPS and HYT were checked in different solvents and methanol was selected as the solvent for dissolving both the drugs. Samples were applied to the plates as 8 mm bands, by means of 25 microlitre Linomat V applicator (Camag, Muttenz Switzerland) equipped with a Hamilton syringe (Bonaduz., Switzerland). The slit dimensions were 6.00 mm × 0.30 mm and the scanning speed was 20 mm s-.[1] A constant application rate of 1 μL/s was used and the space between two bands was 5 mm. The monochromator bandwidth was set at 20 nm, each track was scanned thrice and the baseline correction was used. Ascending development of the plates was performed with Chlroform: Acetonitrile: Glacial Acetic Acid (7:3:1, v/v/v) as mobile phase in a Camag 20 cm × 10 cm twin trough glass chamber (Camag, Muttenz, Switzerland); previously saturated for 30 min with mobile phase. The optimized chamber saturation time for mobile phase was 10 min at room temperature. The length of chromatogram run was 8 cm. The average development time was 20 min. After development, plates were dried. Densitometric scanning was performed on Camag TLC Scanner 3 in the reflectance absorbance mode at 254 nm for all measurements and operated by Wincats software version 3.15 supplied by Anchrom technologists, (Mumbai).
Preparation of Standard Stock Solutions
Standard stock solutions with a concentration of 10μg/mL were prepared in methanol for EPS and HYT respectively. The stock solutions were further diluted to enable application of 1 ng/band for both drugs.
Selection of Analytical Wavelength
Overlay spectra of both drugs was acquired to select appropriate wavelength of analysis.
Optimization of Mobile Phase and Chromatographic Conditions
Chromatographic separation studies were carried out on the stock solution of EPS and HYT. Various solvent mixtures were tried to achieve optimum resolution between both drugs as shown in [Table 1].
|
Sr. No |
Mobile phase |
Remarks |
|
1 |
Chloroform: Acetonitrile: Glacial Acetic Acid (8:3:1, v/v/v) |
Rf values was closer to 1 |
|
2 |
Ethyl acetate: Methanol (9:1, v/v) |
No proper resolution |
|
3 |
Chloroform: Toluene: Methanol (7:2:1, v/v/v) |
Tailing observed |
|
4 |
Chloroform: Acetonitrile: Glacial Acetic Acid (7:3:1, v/v/v) |
Well resolved spots |
Preparation of Mobile Phase
The mobile phase consisting of Chloroform: Acetonitrile: Glacial Acetic Acid (7:3:1, v/v/v) was prepared. Then the mobile phase prepared was transferred to twin trough chamber in which one side of trough a filter paper wetted with mobile phase was kept to cause saturation of chamber faster.
Stability of sample solution
The stability of both drugs in the mobile phase was studied for 12 Hours.
Validation of HPTLC method
Linearity
From stock solution, EPS and HYT were separately spotted on the TLC plate to obtain final concentration 200-700 ng/band respectively. The plate was developed using previously described mobile phase.
Limit of detection (LOD
LOD was calculated from the formula LOD = 3.3 σ/S, where σ = Standard deviation response of the calibration curve, S = Slope of the calibration curve.
Limit of quantification (LOQ
LOQ was calculated from the formula LOQ = 10 σ/S, where σ = Standard deviation response of the calibration curve, S = Slope of the calibration curve.
Specificity
The specificity of the method was ascertained by comparing densitogram of tablet formulation with that of diluent, mobile phase, standard drug sample of EPS and HYT.
Recovery
Accuracy of the method was carried out by applying the method to drug sample to which known amount of EPS and HYT standard powder corresponding to 80, 100 and 120% w/w of label claim were added. The mixtures were analysed by running chromatogram in optimized mobile phase.
Precision
Sample solution of concentration 200-700 ng/band for EPS and HYT were used for studying degree of precision of the developed method. The repeatability of sample application and measurement of peak area of the drug was calculated by repeating the assay six times for each concentration on same day. Intra-day and Inter-day precision was determined by repeating assay three times in same day at different time intervals for intraday precision and on different days for inter day precision studies.
Robustness
Robustness was demonstrated by change in chamber saturation time to 10 min and 20 min and change in wavelength to 252 and 256 nm of detection.
Analysis of tablet formulation
A powder equivalent to 600 mg of EPS and 25 mg of HYT from the trichurated tablet formulation was accurately weighed and dissolved in methanol, sonicated and volume was made to 100 ml with methanol. The solution was filtered through Whatman filter paper no. 41 and volume was adjusted to 100 ml with the same solvent. After filtration, the stock solution was diluted with methanol to give 0.6 µg/ml of EPS and 0.025 µg/ml of HYT. The amount of EPS and HYT present in mixture was calculated.
Result and Discussion
EPS and HYT in methanol showed absorption maxima where the isoabsorptive point of these two graphs was observed at 254 nm as shown in [Figure 2]. Therefore, 254 nm was selected as detection wavelength for both the drugs.
Optimization of mobile phase
After several trials, mixture of Chloroform: Acetonitrile: Glacial Acetic Acid (7:3:1, v/v/v) was chosen as a mobile phase for analysis. Other chromatographic conditions like run length, sample application rate and volume, sample application positions, distance between tracks, detection wavelength were optimized to give reproducible Rf values, better resolution and symmetrical peak shape for the two drugs as shown in [Figure 3], [Figure 4]The Rf value of EPS and HYT was found to be 0.26 ± 0.02 and 0.42 ± 0.02 respectively. The drug solution diluted with mobile phase was found to be stable for 12 hours.
Validation of Analytical method
Linearity
From stock solution, EPS and HYT were separately spotted on the TLC plate to obtain final concentration of 200-700 ng/band. The plate was developed using previously described mobile phase. The results obtained are shown in [Table 2]. The peak areas were plotted against the corresponding concentrations to obtain the calibration graphs ([Figure 5], [Figure 6]).
|
Sr No |
Concentration (ng/band) |
EPS Area* |
HYT Area* |
|
1 |
200 |
2525.20 |
2235.43 |
|
2 |
300 |
3166.73 |
3042.09 |
|
3 |
400 |
4048.65 |
3944.72 |
|
4 |
500 |
4887.54 |
4777.36 |
|
5 |
600 |
5644.36 |
5460.43 |
|
6 |
700 |
6276.51 |
6054.16 |
Limit of Detection and Limit of Quantitation
The LOD and LOQ for EPS and HYT are given in [Table 3].
|
Parameter |
EPS |
HYT |
|
LOD ng/band |
0.811 |
0.332 |
|
LOQ ng/band |
2.45 |
1.007 |
Specificity
The chromatogram of formulation showed only two peaks for EPS and HYT indicating that there is no any interference of any excipients from the formulation.
Accuracy
The % recovery was found to be within the limits of the acceptance criteria and the results are given in [Table 4]. The % recovery value was found to be in the range of 98-102% w/w.
|
Drug (ng/band) |
Amount added (%) |
% Recovery* |
% RSD |
|
EPS |
80 |
99.4 ± 0.238 |
0.3401 |
|
100 |
99.46± 0.208 |
0.2973 |
|
|
120 |
99.48±0.275 |
0.3941 |
|
|
HYT |
80 |
99.26±0.296 |
0.084 |
|
100 |
99.70±0.159 |
0.045 |
|
|
120 |
99.53±0.223 |
0.063 |
|
Drug |
Conc (ng/band) |
Intra-day |
Inter-day |
Repeatability |
|
%mean ± RSD |
%mean± RSD |
%mean ± RSD |
||
|
EPS |
600 |
99.67 ± 0.8956 |
99.41 ± 0.7685 |
99.67 ± 0.8956 |
|
HYT 25 |
99.87 ± 0.5678 |
99.30 ± 0.4534 |
99.87 ± 0.5678 |
|
Drug |
Conc ( ng/band) |
Change saturation time(10min) |
Change saturation time(20min) |
Change in Wavelength At 252nm |
Change in Wavelength At 256nm |
|
EPS |
600 |
99.60± 0.8916 |
99.70± 0.8925 |
99.80± 0.8020 |
99.75 ± 0.2010 |
|
HYT |
25 |
99.50± 0.50 |
99.80± 0.800 |
99.50± 0.8020 |
99.80± 0.300 |
|
Drug |
Label Claim(ng/band) |
% mean ± S.D.* |
% RSD |
|
EPS |
600 |
96.9 ± 0.335 |
0.345 |
|
HYT |
25 |
95.4 ±0.077 |
0.081 |
Precision
The repeatability of sample application and measurement of peak area were expressed in terms of % RSD and was found to be less than 2%.
Precision of the method was assessed in terms of intra-day and inter-day precision as per the recommendations stated in the ICH guidelines. The % RSD for Intra-day precision was thus found to be 0.8956 and 0.5678 EPS and HYT respectively. The % RSD for Inter-day precision was found to be 0.7685 and 0.4534 for EPS and HYT respectively. The results of the same are given in [Table 5].
Robustness
The Robustness of sample application and measurement of peak area were expressed in terms of % RSD and was found to be less than 2%. The results are shown in [Table 6].
Analysis of developed tablet formulation
The amount of EPS and HYT present in tablet formulation was calculated by comparing peak area of sample with that of standard. Densitogram was recorded. The results of analysis of formulation are given in [Table 7].
Two peaks were observed in the chromatogram of the formulation, indicating that there is no interference of any extraneous material. The mean % drug content with %RSD of formulation is given in [Table 7].
Conclusion
A precise, specific, and accurate HPTLC method was developed for simultaneous determination of EPS and HYT from Tablet Formulation without interference from the exicipients. The resolution was achieved using Chloroform: Acetonitrile: Glacial Acetic Acid (7:3:1, v/v/v) as a mobile phase using Aluminum sheet with silica gel G 60 F 254 as a stationary phase. The method was linear in the concentration range of 200-700 ng/band. The method is also robust with respect to chamber saturation time and detection wavelength.
Source of Funding
None.
Conflict of Interest
None.
References
- Bressolle F, Bromet P, Audran M. Validation of liquid chromtography and gas chromatographic methods application to pharmacokinetics. J Chromatogr B Biomed Appl. 1996;686(1):88-94. [Google Scholar] [Crossref]
- Cappiello A, Famiglini G, Palma P, Pierini E, Termopoli V, Trufelli H. Overcoming matrix effects in liquid chromatography-mass spectrometry. Anal Chem. 2008;80(23):9343-8. [Google Scholar] [Crossref]
- Chiu ML, Lawi W, Snyder ST, Wong PK, Liao JC, Gau V. Matrix effects: A challenge toward automation of molecular analysis. J Assoc Lab Automation. 2010;15(3):233-42. [Google Scholar] [Crossref]
- Reid E, Wilson ID. Methodological Survey in Biochemistry and Analysis: Analysis for Drug and Metabolites. Incl Anti-infective Agent. 1990;20:1-57. [Google Scholar]
- . . Food and Drug Administration Guidance for Industry Bioanalytical Method Validation. 2001. [Google Scholar]
- Gad SC. Preclinical development handbook. . 2008. [Google Scholar]
- Kazakevich Y, Lobrutto R. . HPLC for Pharmaceutical Scientists. 2007. [Google Scholar]
- Patel D. Matrix effect in a view of LC-MS/MS: an overview. Int J Pharm and Biol Sci. 2011;2(1):559-64. [Google Scholar]
- Rosing H, Man WY, Doyle E, Bult A, Beijnen JH. Bioanalytical liquid chromatographic method validation- A review of current practices and procedures. J Liq Chrom Rel Technol. 2000;23:329-54. [Google Scholar] [Crossref]
- Said R. Application of new technology LC-MS/MS for determination of therapeutic drugs, Doctoral degree thesis. . 2010. [Google Scholar]
- Thurman EM, Mills MS. Solid-phase extraction: Principles and practice. Chemical analysis: A series of monographs on analytical chemistry and its applications. . 1998. [Google Scholar]
- . 13.Department of Health and Human Services, Food and Drug Administration, Guidance for Industry, Bioanalytical Method Validation, May 2001. . . . [Google Scholar]
- Venn RF. Principles and practice of bioanalysis. . 2000. [Google Scholar]
- Wells DA. . High throughput Bioanalytical sample preparation: methods and automation strategies, Progress in pharmaceutical and biomedical analysis. 2003. [Google Scholar]
- . Wells DA. 2003, High throughput Bioanalytical sample preparation: methods and automation strategies, Progress in pharmaceutical and biomedical analysis, Amsterdam, London, Elsevier, 610. . . . [Google Scholar]
- Dr AV, Kasture. High performance Liquid Chromatography. Pharma Anal Instrumental Methods Nirali Prakashan. 2007;2:48-57. [Google Scholar]
- Willard HH, Merrit LL, Dean JA, Settle FA. Instrumental Method of Analysis. . . [Google Scholar]
- Abstract
- Introduction
- Materials and Methods
- Materials
- Instrumentation and chromatographic condition
- Preparation of Standard Stock Solutions
- Selection of Analytical Wavelength
- Optimization of Mobile Phase and Chromatographic Conditions
- Preparation of Mobile Phase
- Stability of sample solution
- Validation of HPTLC method
- Analysis of tablet formulation
- Result and Discussion
- Conclusion
- Source of Funding
- Conflict of Interest
- References